BCR and cancer: The Prolaris test determines risk of progression (BCR, cancer-specific death) by measuring a proliferation signature of 31 cell cycle progression transcripts [41], whilst Oncotype DX predicts adverse pathology (high grade/stage disease) or poor outcome (BCR) based on 12 genes [42].